Prevalence, risk factors and outcome of digital gangrene in 2684 lupus patients

Lupus

Volumn 18, Issue 12, 2009, Pages 1112-1118

  Liu, A ^a,b   Zhang, W ^a   Tian, X ^a   Zhang, Xuan ^a   Zhang, F ^a   Zeng, X ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

C reactive protein; Digital gangrene; Raynaud's phenomenon; Systemic lupus erythematosus

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL STIMULATING AGENT; CYCLOPHOSPHAMIDE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; PROSTAGLANDIN; WARFARIN;

ADULT; ARTICLE; CHINA; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; DRUG TREATMENT FAILURE; FEMALE; FINGER; FINGER AMPUTATION; FOOT DISEASE; GANGRENE; HAND DISEASE; HUMAN; LABORATORY TEST; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RAYNAUD PHENOMENON; RISK FACTOR; SECONDARY INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; TOE GANGRENE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADULT; FEMALE; FINGERS; GANGRENE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PROGNOSIS; RAYNAUD DISEASE; RISK FACTORS; TOES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349514872     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309106643     Document Type: Article

References (31)

1. da Rocha MC, Vilar MJ, Freire EA, Santiago MB. Arterial occlusion in systemic lupus erythematosus: A good prognostic sign? Clin Rheumatol 2005; 24: 602-605.
2. Kumar N, Choudhary N, Agarwal G, Rizvi Y, Kaul B, Ahlawat R. Extensive medium-vessel vasculitis with SLE: An unusual association. J Clin Rheumatol 2007; 13: 140-142.
3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
4. Vasugi Z, Danda D. Systemic lupus erythematosus with antiphospholipid antibody syndrome: A mimic of Buerger's disease. J Postgrad Med 2006; 52: 132-133.
5. Bhatt SP, Handa R, Gulati GS, et al. Peripheral vascular disease in systemic lupus erythematosus. Lupus 2007; 16: 720-723.
6. Hossny E, Hady HA, Mabrouk R. Anti-centromere antibodies as a marker of Raynaud's phenomenon in pediatric rheumatologic diseases. Pediatr Allergy Immunol 2000; 11: 250-255.
7. Mitwalli AH, Memon NA, Abu-Aisha H, et al. Transverse myelitis in a patient with severe lupus nephritis: A case report. Saudi J Kidney Dis Transpl 2002; 13: 492-497.
8. Bruce IN. 'Not only ... but also': Factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44: 1492-1502.
9. Freire BF, da Silva RC, Fabro AT, dos Santos DC. Is systemic lupus erythematosus a new risk factor for atherosclerosis? Arq Bras Cardiol 2006; 87: 300-306.
10. Nikpour M, Urowitz MB, Gladman DD. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2005; 31: 329-354 vii-viii.
11. Souza AW, Hatta FS, Miranda Jr F, Sato EI. Atherosclerotic plaque in carotid arteries in systemic lupus erythematosus: Frequency and associated risk factors. Sao Paulo Med J 2005; 123: 137-142.
12. Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus-proposed guidelines for risk factor management. Rheumatology (Oxford) 2004; 43: 7-12.
13. Zhang X, Tian X, Zhang F. Premature atherosclerosis-related central nervous system involvement in two cases of systemic lupus erythematosus. J Clin Rheumatol 2007; 13: 211-212.
14. Best LG, Davidson M, North KE, et al. Prospective analysis of mannose-binding lectin genotypes and coronary artery disease in American Indians: The Strong Heart Study. Circulation 2004; 109: 471-475.
15. Von Feldt JM, Scalzi LV, Cucchiara AJ, et al. Homocysteine levels and disease duration independently correlate with coronary artery calcification in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2220-2227.
16. Sarkissian T, Beyene J, Feldman B, McCrindle B, Silverman ED. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum 2007; 56: 631-638.
17. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegård J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with upregulation of the tumor necrosis factor alpha/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2533-2540.
18. Abou-Raya A, el-Hallous D, Fayed H. 8-Isoprostaglandin F2 alpha: A potential index of lipid peroxidation in systemic lupus erythematosus. Clin Invest Med 2004; 27: 306-311.
19. Blankenberg S, Stengel D, Rupprecht HJ, et al. Plasma PAFacetylhydrolase in patients with coronary artery disease: Results of a cross-sectional analysis. J Lipid Res 2003; 44: 1381-1386.
20. Frostegård J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol 2005; 25: 1776-1785.
21. Selzer F, Sutton-Tyrrell K, Fitzgerald SG, et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Arthritis Rheum 2004; 50: 151-159.
22. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
23. TolozaSM, Uribe AG,McGwin JrG, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947-3957.
24. Oksjoki R, Kovanen PT, Pentikäinen MO. Role of complement activation in atherosclerosis. Curr Opin Lipidol 2003; 14: 477-482.
25. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108: 512-515.
26. Asherson RA, Cervera R, Shoenfeld Y. Peripheral vascular occlusionsleading to gangrene and amputations in antiphospholipid antibody positive patients. Ann N Y Acad Sci 2007; 1108: 515-529.
27. Asherson RA, Cervera R, Klumb E, et al. Amputation of digits or limbs in patients with antiphospholipid syndrome. Semin Arthritis Rheum 2008; 38: 124-131.
28. Asherson RA, Derksen RH, Harris EN, et al. Large vessel occlusion and gangrene in systemic lupus erythematosus and 'lupus-like' disease. A report of six cases. J Rheumatol 1986; 13: 740-747.
29. Thiagarajan P. Atherosclerosis, autoimmunity, and systemic lupus erythematosus. Circulation 2001; 104: 1876-1877.
30. Bessant R, Duncan R, Ambler G, et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Arthritis Rheum 2006; 55: 892-899.
31. Hörkk̈ S, Olee T, Mo L, et al. Anticardiolipin antibodies from patients with the antiphospholipid antibody syndrome recognize epitopes in both beta(2)-glycoprotein 1 and oxidized low-density lipoprotein. Circulation 2001; 103: 941-946.